Drug Trial Radar · NCT05951049
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Sep 21, 2023
Primary completion
Sep 28, 2026
Study completion Sep 28, 2026
Sponsor
- Lead sponsor
- Attralus, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novotech (Australia) Pty Limited
- First posted
- Jul 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 open-label extension study to evaluate the long-term safety, tolerability, and clinical activity of AT-02. AT-02 is an investigational medicinal product being developed to treat systemic amyloidosis.
Conditions
- Amyloidosis; Systemic
Interventions
AT02Drug
Dosage Form: Solution for injection/infusion Dosage level: Different dose levels of AT02 Route of Administration: Intravenous use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, frequency, and severity of Treatment-emergent adverse events (TEAEs) as assessed National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0)Time frame: Up to 112 weeks
- To assess the safety and tolerability of AT-02 through change from baseline in clinical laboratory resultsTime frame: Up to 112 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Kansas City
Kansas City, Kansas
Cleveland Clinic
Cleveland, Ohio
OHSU (Oregon Health & Science University)
Portland, Oregon
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.